Patents by Inventor Andrew J. Perlman

Andrew J. Perlman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 11026920
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 2, 2020
    Date of Patent: June 8, 2021
    Assignee: VYNE THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS
    Publication number: 20200306224
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: March 2, 2020
    Publication date: October 1, 2020
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • Use of NK-1 receptor antagonists in pruritus
    Patent number: 10702499
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: July 7, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 10617671
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 14, 2020
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS
    Publication number: 20200054603
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: March 25, 2019
    Publication date: February 20, 2020
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS
    Publication number: 20200054604
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: March 25, 2019
    Publication date: February 20, 2020
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • Use of NK-1 receptor antagonists in pruritus
    Patent number: 10278952
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: May 7, 2019
    Assignee: Menlo Therapeutics Inc.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 10278953
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: May 7, 2019
    Assignee: Menlo Therapeutics Inc.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS
    Publication number: 20180325867
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: April 18, 2018
    Publication date: November 15, 2018
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS
    Publication number: 20180325866
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: April 10, 2018
    Publication date: November 15, 2018
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 9974769
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 22, 2018
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Use of NK-1 receptor antagonists in pruritus
    Patent number: 9968588
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: May 15, 2018
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS
    Publication number: 20170348283
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 7, 2017
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS
    Publication number: 20170348282
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: June 16, 2017
    Publication date: December 7, 2017
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • Use of NK-1 receptor antagonists in pruritus
    Patent number: 9737508
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 22, 2017
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 9737507
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: August 22, 2017
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Use of NK-1 receptor antagonists in pruritus
    Patent number: 9707209
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: July 18, 2017
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • Use of NK-1 receptor antagonist serlopitant in pruritus
    Patent number: 9707208
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: July 18, 2017
    Assignee: MENLO THERAPEUTICS INC.
    Inventors: Xiaoming Zhang, Edward F. Schnipper, Andrew J. Perlman, James W. Larrick
  • USE OF NK-1 RECEPTOR ANTAGONISTS IN PRURITUS
    Publication number: 20170065558
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: September 20, 2016
    Publication date: March 9, 2017
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK
  • USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS
    Publication number: 20170065557
    Abstract: The invention relates to methods for treating pruritus with NK-1 receptor antagonists such as serlopitant. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonists such as serlopitant. In addition, the invention encompasses treatment of a pruritus-associated condition with serlopitant and an additional antipruritic agent, and the use of serlopitant as a sleep aid, optionally in combination with an additional sleep-aiding agent.
    Type: Application
    Filed: September 19, 2016
    Publication date: March 9, 2017
    Inventors: Xiaoming ZHANG, Edward F. SCHNIPPER, Andrew J. PERLMAN, James W. LARRICK